Evidence map›Paper›PMID 30561773›Full record

ArticleCancer2019

High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Lisanne S Rigter, Manon C W Spaander, Berthe M P Aleman, Tanya M Bisseling, Leon M Moons, Annemieke Cats, Pieternella J Lugtenburg, Cecile P M Janus, Eefke J Petersen, Judith M Roesink and 9 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Guideline
  2. Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.International journal of particle therapy · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  10. Article
  11. Article
  12. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Lisanne S RigterDepartment of Gastroenterology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Manon C W SpaanderDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Berthe M P AlemanDepartment of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Tanya M BisselingDepartment of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Leon M MoonsDepartment of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
Annemieke CatsDepartment of Gastroenterology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Pieternella J LugtenburgDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Cecile P M JanusDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Eefke J PetersenDepartment of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
Judith M RoesinkDepartment of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
Richard W M van der MaazenDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Petur SnaebjornssonDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ernst J KuipersDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Marco J BrunoDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.ORCID 0000-0002-4363-0745
Gerrit A MeijerDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jan Paul de BoerDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Flora E van LeeuwenDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Monique E van LeerdamDepartment of Gastroenterology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
The Netherlands Cancer Institute · NLDutch Cancer Society · NLErasmus MC · NLErasmus MC Cancer Institute · NLRadboud University Nijmegen · NLUtrecht University · NLAmsterdam UMC Location University of Amsterdam · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHodgkin lymphoma (HL) survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have an increased risk of colorectal cancer (CRC). This study was aimed at evaluating the prevalence of colorectal neoplasia in HL survivors.

methodsThis multicenter cohort study assessed the diagnostic yield of advanced colorectal neoplasia detected by a first surveillance colonoscopy among HL survivors treated with abdominal radiotherapy and/or procarbazine. Advanced colorectal neoplasia included advanced adenomas (high-grade dysplasia, ≥25% villous component, or ≥10-mm diameter), advanced serrated lesions (dysplasia or ≥10-mm diameter), and CRC. The results were compared with those for a Dutch general population cohort that underwent a primary screening colonoscopy (1426 asymptomatic individuals 50-75 years old). This study demonstrated the results of a predefined interim analysis.

resultsA colonoscopy was performed in 101 HL survivors, who were significantly younger (median, 51 years; interquartile range [IQR], 45-57 years) than the general population controls (median, 60 years; IQR, 55-65 years; P < .001). The prevalence of advanced neoplasia was higher in HL survivors than controls (25 of 101 [25%] vs 171 of 1426 [12%]; P < .001). Advanced adenomas were detected in 14 of 101 HL survivors (14%) and in 124 of 1426 controls (9%; P = .08). The prevalence of advanced serrated lesions was higher in HL survivors than controls (12 of 101 [12%] vs 55 of 1426 [4%]; P < .001). Serrated polyposis syndrome was present in 6% of HL survivors and absent in controls (P < .001).

conclusionsHL survivors treated with abdominal radiotherapy and/or procarbazine have a high prevalence of advanced colorectal neoplasia. The implementation of a colonoscopy surveillance program should be considered.

Indexed as

AgedCancer SurvivorsCohort StudiesColonic PolypsColonoscopyColorectal NeoplasmsFemaleHodgkin DiseaseHumansMaleMiddle AgedPrevalenceProcarbazineProcarbazinecolorectal cancer (CRC) screeningepidemiologypolyps/adenomas

Identifiers

PMID30561773
PMCPMC6590398
OpenAlexW2904107108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.